Stock MIRA MIRA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases MIRA Pharmaceuticals, Inc.

Equities

MIRA

US60458C1045

Market Closed - Nasdaq
Other stock markets
 02:00:00 25/06/2024 am IST 		5-day change 1st Jan Change
0.71 USD -0.98% Intraday chart for MIRA Pharmaceuticals, Inc. -1.38% -32.37%
24/06 MIRA Pharmaceuticals, Inc. Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing CI
10/06 MIRA Pharmaceuticals, Inc. Announces Positive Preclinical Study Results for Its Novel Oral Ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing
PR
Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year
PR
Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance
PR
MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog
PR
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog
PR
Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission
PR
MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor
PR
MIRA Pharmaceuticals Provides Corporate Update
PR
MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations
PR
MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%
PR
MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time
PR
MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a
PR
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
PR
MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot
PR
MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts
PR
MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit
PR
MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIRA Stock
  4. News MIRA Pharmaceuticals, Inc.
  5. Press Releases